UNC Health

     System Formulary Restriction:

     Tarlatamab-dlle injection orders must be signed by a Hematology/Oncology Attending Physician  

     Inpatient use of tarlatamab-dlle injection is restricted to patients who meet one of the following criteria:

• Initiation/new-start treatment for extensive stage-small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
• Re-initiation of treatment in patients with ES-SCLC who have experienced a treatment delay that requires re-initiation with step-up doses
• Continuation of therapy in patients with ES-SCLC who have experienced significant adverse drug reactions (e.g., Grade ≥2 CRS; ICANS, neurological toxicity) necessitating inpatient admission for subsequent cycles

     All other use is restricted to outpatient encounters or clinic use only (i.e., no inpatient use)

• Lexicomp
• Micromedex
• UpToDate
• FDA Daily Med